Clinical Trial: Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: A Pilot Study, Prospective, Non-Randomized, Non-Blinded, Single-Center Study Evaluating the Response of Continuous Recombinant Antithrombin (ATryn) Infusion in Postcardiotomy ECMO Patients
Brief Summary: The objective of this study will be to prospectively evaluate the response of a continuous infusion of recombinant human antithrombin concentrate (rhAT) (ATRYN®) to achieve and maintain the AT activity within a specified range in adult patients that require extracorporeal membrane oxygenation (ECMO) following cardiopulmonary bypass (CPB) and cardiac surgery.
Detailed Summary:
Sponsor: Mayo Clinic
Current Primary Outcome: Percentage of time within the serum AT level target range of 80-100% [ Time Frame: 72 hour infusion period ]
Original Primary Outcome: Percentage of time within the serum AT level target range of 80-100% [ Time Frame: 72 hour infusion period ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Mayo Clinic
Dates:
Date Received: March 21, 2017
Date Started: July 1, 2017
Date Completion: October 2017
Last Updated: April 12, 2017
Last Verified: April 2017